Drug Eluting Balloon Catheter Market Trends and Forecast
The future of the global drug eluting balloon catheter market looks promising with opportunities in the hospital, ambulatory surgical center, and cardiac catheterization laboratory markets. The global drug eluting balloon catheter market is expected to grow with a CAGR of 18% from 2025 to 2031. The major drivers for this market are the increasing incidence of cardiovascular diseases, the growing preference for minimally invasive procedures, and the rising adoption of advanced medical technologies.
• Lucintel forecasts that, within the indication category, coronary artery disease is expected to witness higher growth over the forecast period.
• Within the end use category, hospital is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Drug Eluting Balloon Catheter Market
The drug eluting balloon catheter market is rapidly evolving as a consequence of developments in material science, drug release mechanisms, and clinical knowledge. These trends demonstrate an ongoing effort to make DEBs both safe and effective, expand their clinical use, and optimize long-term outcomes for patients, ultimately transforming interventional vascular therapies.
• Transition to Sirolimus-Coated Balloons: Another significant new trend is increased interest in and creation of sirolimus-coated balloons as a substitute for paclitaxel-coated DEBs. Although paclitaxel has been the most established, recent safety issues and the need for better drug kinetics have fueled inquiry into sirolimus. Sirolimus provides effective antiproliferative actions with potentially improved biocompatibility and less inflammation. This transformation is intended to optimize drug release properties and increase long-term patency, with a chance of offering safer and more effective treatment for more patient populations.
• Growth into New Anatomical Applications: The market is seeing a strong trend of extending DEB applications from coronary and peripheral arteries into new anatomical regions. It involves the application of DEBs for the treatment of stenosis in dialysis access arteriovenous fistulas, superficial femoral artery lesions, and possibly in venous procedures. This growth is propelled by mounting clinical evidence illustrating the utility of DEBs in other vascular beds where conventional stents are likely to be problematic, hence expanding the market as well as meeting unmet clinical needs in specialized vascular interventions.
• Biodegradable Polymers and Innovative Excipients Development: One trend involves the creation of DEBs made of biodegradable polymers and new excipients for drug delivery. Conventional DEBs tend to be coated with non-biodegradable materials, which can lead to residue in the vessel. Biodegradable polymers seek to provide more controlled and targeted drug release, as well as reduce long-term inflammation responses. New excipients are being explored to further maximize drug transfer efficiency between the balloon and the vessel wall for improved drug absorption and retention, which is essential in minimizing restenosis and enhancing vessel healing.
• Emphasis on Certain Lesion Types and Complex Cases: There is a greater trend towards the creation of DEBs with specifications to particular lesion categories and progressively sophisticated vascular conditions. These range from balloons specifically for in-stent restenosis, tiny vessel disease, bifurcations, and heavily calcified lesions where more conventional treatments are suboptimal. Industry players are creating innovative balloons with novel balloon shapes, coating stripes, and drug loading to best deliver in these challenging situations, providing interventionalists with more accurate tools to tackle hard-to-treat pathologies and enhance procedural success.
• Integration with Intravascular Imaging for Accurate Delivery: A significant forthcoming trend is the use of DEB procedures in combination with sophisticated intravascular imaging modalities like Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT). These imaging modalities give detailed images of the vessel wall and lumen, enabling accurate lesion evaluation, proper balloon sizing, and confirmation of drug delivery. This consolidation is intended to enhance procedural success by facilitating precise DEB placement and medication transfer, resulting in enhanced long-term vessel patency and decreased repeat intervention requirements.
These new trends are working together to redefine the drug eluting balloon catheter market by stretching the frontiers of technology and broadening clinical applicability. The market is increasingly specialized, targeted, and patient-focused, trending towards therapies that are more effective across a broader spectrum of vascular diseases, thus establishing DEBs as an indispensable instrument in contemporary interventional medicine.
Recent Development in the Drug Eluting Balloon Catheter Market
The drug eluting balloon catheter market has seen numerous notable recent advancements, which deeply influenced its technological capabilities, clinical uses, and market acceptance. These developments are fueled by the continuous demand for efficient solutions to avoid restenosis in vascular interventions without the permanent implant.
• FDA Approval for Coronary Artery Disease Applications: One significant recent trend is the growing number of regulatory clearances, especially from the FDA, for Drug Eluting Balloons (DEBs) in use for coronary artery disease indications. DEBs have been used more commonly in peripheral interventions in the past. The FDA clearance of devices such as Boston Scientific’s AGENT Drug-Coated Balloon for in-stent restenosis (ISR) in coronary arteries is an important milestone. This innovation extends the market’s presence into a volume segment, providing interventional cardiologists with a new, efficient solution for difficult cases, and possibly minimizing the frequency of repeat stenting.
• Innovation in Drug Formulations and Excipients: Recent innovations include major improvements in drug formulation and excipients applied on DEBs. The manufacturers are concentrating on optimizing the coating technology to facilitate effective and uniform drug delivery to the vessel wall, in addition to sustained drug release. Innovations involve novel excipients that improve drug solubility and absorption, and better coating integrity to reduce drug washout during delivery. This has a direct influence on the effectiveness of the balloon in the prevention of restenosis, resulting in more predictable and durable clinical results.
• Increasing Use in Peripheral Artery Disease Treatment: The market has experienced a significant recent trend in the increasing use of DEBs for the treatment of peripheral artery disease (PAD). DEBs are now a favored choice for lesions of the superficial femoral artery (SFA) and popliteal artery as they can administer localized drug therapy without the use of a permanent metal scaffold, which is helpful in highly mobile vessels. This growing clinical acceptance in PAD is fueled by compelling clinical trial data showing superior patency rates to uncoated balloons.
• Emergence of Sirolimus-Coated Balloons: A recent highlight is the discovery and growing research into sirolimus-coated balloons as a substitute to the prevalent paclitaxel-coated balloons. Although paclitaxel has worked well, there have been concerns about possible long-term mortality signals driving interest in sirolimus, a drug with a different safety profile and anti-proliferative action. This marks the industry’s ongoing quest to innovate and offer safer, yet equally effective alternatives, giving rise to new product pipelines and clinical trials.
• Greater Emphasis on Renal Denervation and Dialysis Access: Recent advances involve greater emphasis on the prospective use of DEBs in renal denervation and for the treatment of stenosis in arteriovenous fistulas (AVFs) for dialysis access. DEBs provide a likely solution to ensure patency of AVFs, which are vital for patients receiving hemodialysis and commonly experience high rates of restenosis. This extension into specialized vascular access and other niche fields illustrates the adaptability of DEB technology and its potential to meet unmet clinical demands outside of more conventional coronary and peripheral uses.
These five major advancements are significantly influencing the drug eluting balloon catheter market by widening its clinical application, improving product performance, and pushing innovation towards more safe and flexible solutions. The market is transforming into an increasingly central component of interventional vascular treatment, presenting a useful substitute or complement for stent-based treatments.
Strategic Growth Opportunities in the Drug Eluting Balloon Catheter Market
The drug eluting balloon catheter market offers strong strategic growth opportunities across major applications based on growing prevalence of cardiovascular and peripheral vascular conditions and DEB’s superior benefit over traditional treatment options. Recognizing and leveraging these application-specific opportunities will be vital for companies intending to increase their market presence and fuel innovation.
• In-Stent Restenosis of Coronary Arteries: Treating in-stent restenosis (ISR) in coronary arteries is a top strategic growth area. Even with improvements in drug-eluting stents, ISR is still a formidable challenge. DEBs present an attractive alternative by providing anti-proliferative drugs without placing another coat of metal, potentially making future interventions more difficult. Strategic growth entails creating DEBs specifically tailored for ISR, obtaining strong clinical evidence of their superiority to re-stenting or plain balloon angioplasty, and obtaining good reimbursement policies to support widespread adoption.
• Small Vessel Disease and Bifurcation Lesions: Treatment of bifurcation and small vessel disease in coronary arteries presents a specialized but significant strategic growth area. These are difficult anatomies for stent placement in many cases and are related to increased restenosis rates. DEBs provide even drug delivery in these anatomies without permanent scaffolding, leaving the treatment options open in the future. Strategic emphasis is on developing DEBs with better deliverability in curved anatomy and on techniques for targeted drug delivery in bifurcation lesions.
• Peripheral Artery Disease of Lower Extremities: The treatment of peripheral artery disease (PAD), particularly of the superficial femoral artery (SFA) and popliteal artery, is a significant strategic expansion opportunity. These arteries are extremely mobile, rendering stents susceptible to fracture and restenosis. DEBs provide a stent-free solution ensuring vessel patency and mobility. Strategic expansion here means creating DEBs with increased longevity, extended lengths of balloons, and improved drug delivery for the treatment of a broad array of peripheral lesions, taking advantage of their proven superiority in averting restenosis.
• Arteriovenous Fistula Stenosis in Patients on Dialysis: Treatment of arteriovenous fistula (AVF) stenosis in hemodialysis patients is an important and increasing strategic growth possibility. AVFs are essential for dialysis but often become stenotic, resulting in access loss. DEBs have demonstrated the potential to preserve AVF patency through the inhibition of neointimal hyperplasia. Strategic emphasis is on the creation of DEBs tailored to the specialized anatomy and flow characteristics of AVFs, partnering with nephrology and vascular access experts, and trials to prove long-term patency advantage.
• De Novo Coronary Lesions in Specific Patient Groups: Although drug-eluting stents are still the gold standard for de novo coronary lesions, a strategic growth opportunity lies for DEBs in specific patient groups who are not ideal candidates for permanent implants (e.g., patients with increased bleeding risk, planned future bypass surgery, or patients who prefer stent-free treatment). Strategic emphasis is placed on performing clinical trials to demonstrate DEB efficacy and safety in these specific patient populations and positioning DEBs as an effective, non-stent option in relevant clinical settings.
These strategic growth opportunities are deeply influencing the drug eluting balloon catheter market by expanding its applications, accelerating product innovation, and filling unmet clinical needs in different vascular territories. They are forcing manufacturers to innovate more specialized and powerful solutions, establishing DEBs as a must-have tool in contemporary interventional cardiology and vascular medicine.
Drug Eluting Balloon Catheter Market Driver and Challenges
The drug eluting balloon catheter market is strongly influenced by an active interaction of several technological, economic, and regulatory factors. They are both strong drivers of market growth and significant barriers, impacting product development, adoption levels, and the strategic planning of companies. It is important to have thorough knowledge of these drivers as well as obstacles so that stakeholders can create effective strategies and negotiate the intricate landscape of interventional vascular treatment.
The factors responsible for driving the drug eluting balloon catheter market include:
1. Increasing Incidence of Cardiovascular and Peripheral Artery Diseases: One of the major drivers is the increasing global incidence of cardiovascular diseases (CAD) and peripheral artery disease (PAD). Lifestyle modifications, aging populations, and higher rates of diabetes and obesity are the reasons for blockages and constriction of arteries. This large pool of patients translates directly into demand for interventional procedures, including ones using DEBs, to avoid restenosis and restore blood flow, driving market growth.
2. Growing Demand for Minimally Invasive Treatments: A major market driver is the worldwide trend toward minimally invasive procedures (MIPs). MIPs have many advantages, such as smaller incisions, less pain, abbreviated hospitalization, and quicker recovery, over the standard open approaches. DEBs are central to these interventions, delivering drug only where needed without a permanent implant, which reflects both patient and physician desires for less aggressive and more effective treatments.
3. Advantages of DEBs Over Traditional Bare Metal Stents: The inherent benefits of drug eluting balloons compared to bare metal stents (BMS) in specific clinical contexts are a key driver. DEBs have the advantage of not resulting in a permanent implant, which is a benefit in very mobile vessels (such as the superficial femoral artery), in-stent restenosis, or where there is the potential for future surgery. This "leave nothing behind" strategy mitigates long-term risk from permanent implants such as late stent thrombosis and subsequent re-intervention.
4. Increasing Clinical Evidence and Wider Indications: Mounting favorable clinical evidence from trials attesting to the effectiveness and safety of DEBs is a strong impetus. With stronger data coming in showing better patency rates and lower re-intervention rates than traditional angioplasty, doctors become increasingly assured about DEB technology. This increasing body of proof also causes wider indications of DEBs beyond original applications, creating new lines of treatment and patient populations.
5. Positive Reimbursement Policies in Developed Markets: Positive reimbursement policies in the most important developed healthcare markets play a critical role in the widespread use of DEBs. Government and private payer reimbursement sufficient to support the cost of DEB technology stimulates hospitals and clinics to adopt DEBs and enables patients to receive these advanced therapies. Secure and stable reimbursement makes economic sense for DEB procedures, driving market growth and utilization directly.
Challenges in the drug eluting balloon catheter market are:
1. Excessive Cost of DEB Catheters: A notable drawback is the relatively high cost of drug eluting balloon catheters when compared to plain angioplasty balloons or certain bare metal stents. Their higher price tag can restrict their uptake, especially in budget-constrained healthcare systems or in developing economies. Cost-effectiveness continues to be an overriding concern for payers and hospitals, potentially deterring wider market share penetration despite clinical value.
2. Issues of Paclitaxel Safety: Though broadly utilized, historical safety issues related to paclitaxel, the medication contained in most DEBs, have been a major challenge. A meta-analysis reported in 2018 indicated a possible long-term survival signal with paclitaxel-coated devices, though more recent studies have provided more subtle views. These residual doubts have effects on physician and patient confidence, resulting in hesitant uptake and spurring the quest for new drug coatings such as sirolimus.
3. Technical Complexity of Drug Coating Technology and Production: The technical complexity of the drug coating technology and the highly exacting manufacturing processes of DEBs is a significant challenge. Ensuring uniform distribution of the drug, optimal release kinetics, and stable adhesion to the balloon surface with catheter deliverability requires advanced engineering. Uniformity is liable to impact device performance and clinical efficacy, and rigorous quality control and heavy R&D investment are therefore necessary.
In summary, the drug eluting balloon catheter market is witnessing high growth fueled by the rising global burden of cardiovascular and peripheral artery disease, a high preference for minimally invasive interventions, the inherent benefits of DEBs over conventional stents, expanding clinical data, and favorable reimbursement policies in the major markets. But its growth is challenged also by the expense of the devices, the past safety issues related to paclitaxel, and the built-in vagaries of drug coating technology and production. It will be important for the marketplace to overcome these multidimensional challenges through ongoing innovation, cost-containment measures, and strong clinical validation in order to maintain long-term growth and its central position in driving interventional vascular therapies.
List of Drug Eluting Balloon Catheter Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies drug eluting balloon catheter companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the drug eluting balloon catheter companies profiled in this report include-
• Cardionovum
• Cook Medical
• Cordis Corporation
• Abbott Laboratories
• Meril Life Sciences
• Jotech
• MicroPort Scientific Corporation
Drug Eluting Balloon Catheter Market by Segment
The study includes a forecast for the global drug eluting balloon catheter market by indication, raw material, end use, and region.
Drug Eluting Balloon Catheter Market by Indication [Value from 2019 to 2031]:
• Coronary Artery Disease
• Peripheral Vascular Disease
Drug Eluting Balloon Catheter Market by Raw Material [Value from 2019 to 2031]:
• Polyurethane
• Nylon
• Others
Drug Eluting Balloon Catheter Market by End Use [Value from 2019 to 2031]:
• Hospitals
• Ambulatory Surgical Centers
• Cardiac Catheterization Laboratories
• Others
Drug Eluting Balloon Catheter Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Drug Eluting Balloon Catheter Market
The drug eluting balloon catheter market is witnessing strong growth and tremendous innovation, fueled by the growing worldwide burden of cardiovascular diseases, the widening demand for minimally invasive interventions, and the ongoing search for better patient outcomes without the use of permanent implants. DEBs possess a special benefit by locally delivering anti-proliferative drugs to the vessel wall, with the goal of inhibiting restenosis—the re-narrowing of the arteries—following angioplasty. This dynamic market is broadening its applications from coronary arteries to peripheral vessels and other difficult-to-reach vascular territories, indicative of its increasing significance in interventional radiology and cardiology.
• United States: In the United States, current developments in the drug eluting balloon catheter market are characterized by greater regulatory approvals and an emphasis on clinical evidence. For instance, the AGENT Drug-Coated Balloon of Boston Scientific Corporation was approved by FDA in March 2024, a major development in the treatment of in-stent restenosis in coronary arteries. The demand for DEBs is also increasing in peripheral artery disease (PAD) interventions in the market due to the increasing geriatric population and the benefits of DEBs over older generation stents in specific lesion types.
• China: China’s drug eluting balloon catheter market is experiencing a steep growth, led by the high incidence of cardiovascular conditions and rising investment in healthcare infrastructure. Recent trends involve more local manufacturers entering the market with an aim to offer low-cost solutions. There is much emphasis put on developing drug coating technologies and excipient formulations in order to further improve the efficacy of drug delivery. The Chinese expert opinion on clinical uses of drug-coated balloons has also been revised in accordance with changing clinical practices and new indications for DEB use.
• Germany: Germany’s drug eluting balloon catheter market is dominated by insistence on high-quality clinically proven devices and robust uptake in interventional cardiology. Recent trends have involved the continued use of paclitaxel-coated balloons as a first-line treatment for peripheral artery disease and in-stent restenosis. German industry and research organizations are proactively involved in investigations to maximize drug delivery and evaluate long-term results. Beneficial reimbursement policies also support the consistent expansion and extensive incorporation of DEB technology into the German healthcare system.
• India: The Indian Drug Eluting Balloon Catheter market is growing strongly, stimulated by a high prevalence of cardiovascular diseases, rising healthcare spending, and an expanding number of interventional cardiologists. Recent trends have seen an upsurge in the demand for both coronary and peripheral DEBs. Although paclitaxel is still the lead drug, there is new interest in sirolimus-coated balloons. Local players, as well as multinational ones, are broadening their product ranges to address the varied needs of the Indian patient population, usually with a focus on cost-effectiveness in addition to clinical effectiveness.
• Japan: Japan’s drug eluting balloon catheter market is characterized by focus on accuracy, advanced technology, and strict clinical assessment. Developments in recent times involve the growing usage of DEBs for the treatment of both coronary and peripheral artery disease, especially where stents are not suitable for complex lesions. Japanese regulatory agencies and medical associations are stringent when assessing new devices to maintain high standards of safety and efficacy. Research into new drug formulations and coating methods is also ongoing to further enhance treatment performance, pushed by the need for an aging population.
Features of the Global Drug Eluting Balloon Catheter Market
Market Size Estimates: Drug eluting balloon catheter market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Drug eluting balloon catheter market size by indication, raw material, end use, and region in terms of value ($B).
Regional Analysis: Drug eluting balloon catheter market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different indication, raw material, end use, and regions for the drug eluting balloon catheter market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the drug eluting balloon catheter market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for drug eluting balloon catheter market?
Answer: The global drug eluting balloon catheter market is expected to grow with a CAGR of 18% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the drug eluting balloon catheter market?
Answer: The major drivers for this market are the increasing incidence of cardiovascular diseases, the growing preference for minimally invasive procedures, and the rising adoption of advanced medical technologies.
Q3. What are the major segments for drug eluting balloon catheter market?
Answer: The future of the drug eluting balloon catheter market looks promising with opportunities in the hospital, ambulatory surgical center, and cardiac catheterization laboratory markets.
Q4. Who are the key drug eluting balloon catheter market companies?
Answer: Some of the key drug eluting balloon catheter companies are as follows:
• Cardionovum
• Cook Medical
• Cordis Corporation
• Abbott Laboratories
• Meril Life Sciences
• Jotech
• MicroPort Scientific Corporation
Q5. Which drug eluting balloon catheter market segment will be the largest in future?
Answer: Lucintel forecasts that, within the indication category, coronary artery disease is expected to witness higher growth over the forecast period.
Q6. In drug eluting balloon catheter market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the drug eluting balloon catheter market by indication (coronary artery disease and peripheral vascular disease), raw material (polyurethane, nylon, and others), end use (hospitals, ambulatory surgical centers, cardiac catheterization laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Drug Eluting Balloon Catheter Market, Drug Eluting Balloon Catheter Market Size, Drug Eluting Balloon Catheter Market Growth, Drug Eluting Balloon Catheter Market Analysis, Drug Eluting Balloon Catheter Market Report, Drug Eluting Balloon Catheter Market Share, Drug Eluting Balloon Catheter Market Trends, Drug Eluting Balloon Catheter Market Forecast, Drug Eluting Balloon Catheter Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.